Evidence map›Paper›PMID 41178182›Full record

Trial reportJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption - A prospective monocenter pilot study.

Maike M Holtsche, Nina van Beek, Christoph M Hammers, Artem Vorobyev, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maike M HoltscheDepartment of Dermatology, University of Lübeck, Lübeck, Germany.ORCID https://orcid.org/0000-0002-5318-5796
Nina van BeekDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Christoph M HammersDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Artem VorobyevDepartment of Dermatology, University of Lübeck, Lübeck, Germany.ORCID https://orcid.org/0000-0002-1542-0732
Michael KasperkiewiczDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
Nina SchumacherDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Philip MuckDepartment of Internal Medicine, University of Lübeck, Lübeck, Germany.
Enno SchmidtDepartment of Dermatology, University of Lübeck, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesBullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long-term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA) in refractory patients. Here we investigated the safety and efficacy of IA in severe and/or refractory BP patients. PATIENTS AND

methods10 BP patients (3 women, 7 men; mean age 69.7 years; range 52-81 years) were treated with IA on three consecutive days (LigaSorb

resultsWithin 2 and 6 months after IA, 50% and 90% of patients showed complete remission on therapy, respectively. In all patients, serum anti-BP180 IgG levels decreased significantly by an average of 89% and 73% immediately after the third IA and 4 weeks later, respectively. A total of 56 adverse events (AE) occurred during the 12-month follow-up. The majority of AE were of severity grade 2 (50%), 15 AE were classified as severe (grade 3-4).

conclusionsIA can be considered as a relatively safe and effective adjuvant therapy for patients with severe or refractory BP.

Indexed as

Immunosorbent TechniquesPemphigoid, BullousAgedAged, 80 and overChemotherapy, AdjuvantCombined Modality TherapyDapsoneFemaleHumansImmunosuppressive AgentsMaleMiddle AgedPilot ProjectsPrednisoloneProspective StudiesTreatment OutcomeDapsoneImmunosuppressive AgentsPrednisoloneautoimmune blistering diseaseBP180bullous pemphigoidimmunoadsorption

Identifiers

PMID41178182
PMCPMC13059066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.